Adaptive external beam radiotherapy added to Lutetium-177 PSMA therapy for metastatic castration-resistant prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pragmatic, registry-based phase 2 study compares standard 177Lu-PSMA therapy with an added adaptive external beam radiotherapy (EBRT) approach in men with metastatic castration-resistant prostate cancer. EBRT is delivered between cycles of radioligand treatment to boost underdosed metastatic sites while maintaining overall safety. The trial is multi-center and randomized, aiming to see if the combined approach reduces skeletal-related events without increasing toxicity. Eligible patients have measurable metastases suitable for EBRT and are receiving 177Lu-PSMA, with good performance status. Outcomes will inform whether adaptive EBRT can enhance the effectiveness of PSMA-targeted radioligand therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Receiving 177Lu-PSMA for mCRPC
* ECOG 0-1
* Presence of a discernible metastatic burden suitable for EBRT
* Receiving bone protective therapy

Exclusion Criteria:

* no exclusions

Where it's running

• Centre Hospitalier de l'Université-de-Montréal
  Montreal, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Cynthia Menard, MD — Centre hospitalier de l'Université de Montréal (CHUM)
• Study coordinator: Mom Phat
• Email: mom.phat.chum@ssss.gouv.qc.ca
• Phone: 514-890-8000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sacituzumab tirumotecan plus tagitanlimab for aggressive and neuroendocrine prostate cancer

  This trial tests whether combining sacituzumab tirumotecan with the immunotherapy tagitanlimab helps people with aggressive variant or neuroendocrine prostate cancer that has progressed after newer hormonal treatments.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07179783

• Blood-based tumor DNA testing during PSMA radioligand therapy

  This project will test whether blood-based liquid biopsies taken before, during, and after PSMA radioligand therapy can help predict outcomes for men with metastatic castration-resistant prostate cancer.

  Recruiting at 3 sites Wuerzburg University Hospital · Augsburg and 2 other locations · NCT07118436

• JUR-003 in adults with advanced prostate cancer

  This first-in-human study tests JUR-003 to see if it is safe and tolerable and to get an early sense of activity in adults with metastatic or advanced prostate cancer.

  Recruiting at 4 sites Phase 1 TCG Labs Soleil · Grand Rapids, Michigan and 3 other locations · NCT07824349

• SRT-017 radioligand therapy in PSMA-positive metastatic castration-resistant prostate cancer

  This study tests SRT-017 given by IV infusion to men with PSMA-positive metastatic castration-resistant prostate cancer to see if it is safe and tolerable and to gather early signals of anti-tumor activity.

  Recruiting Early Phase 1 Affiliated Hospital of Jiangnan University · Wuxi, Jiangsu · NCT07798778

• Rinzimetostat plus darolutamide in metastatic castration-resistant prostate cancer after abiraterone failure

  This study tests whether adding rinzimetostat to darolutamide helps people with metastatic castration-resistant prostate cancer who previously took abiraterone.

  Recruiting at 15 sites Phase 3 ORIC Pharmaceuticals · Glendale, California and 14 other locations · NCT07723248

• FX-111 safety and pharmacokinetics in metastatic castration-resistant prostate cancer

  This study tests whether FX-111 is safe and can help treat metastatic castration-resistant prostate cancer in adult men.

  Recruiting at 7 sites Phase 1 Flare Therapeutics Inc. · Los Angeles, California and 9 other locations · NCT07719361

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.